Olshavsky et al. [88] reported that cyclin D3 was able to bind to and attenuate androgen receptor activity in prostate cancer cells, where cyclin D3 overexpression inhibited cell proliferation in androgen-dependent cells. Here, CCND3 is linked to prostate carcinoma.